Next Earnings date is expected on
02/02/2022
AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...
AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...
AbbVie (ABBV) said Friday that the US FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis. According...
AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...
AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.
Diving into two strong stocks that also pay a dividend that investors might want to consider buying...
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc....
| Address | 1 North Waukegan Road North Chicago, Illinois 60064-6400 |
| Phone | +1.847.932.7900 |
| Number of Employees | 30,000 |
| Recent SEC Filing | 01/05/2022 4 |
| Chairman & Chief Executive Officer | Richard A. Gonzalez |
| Vice Chairman-Management Board & President | Michael E. Severino |
| Executive Vice President-Operations | Azita Saleki-Gerhardt |
| CFO, Vice Chairman-Finance & Commercial Operations | Robert A. Michael |
| Price Open | $135.50 |
| Previous Close | $134.23 |
| 52 Week Range | $101.81 - 138.30 |
| Market Capitalization | $241.3 B |
| Shares Outstanding | 1.8 B |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major |
| Current Dividend / Yield | $1.41 / 4.20% |
| Dividend Ex-Date | 01/13/2022 |
| Dividend Pay-Date | 02/15/2022 |
| Dividend Yield 5 Year Average | 4.12% | Next Earnings Announcement | 02/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 31.42 |
| Earnings per Share | $7.46 |
| Beta vs. S&P 500 | N/A |
| Revenue | $32.8 B |
| Net Profit Margin | 13.51% |
| Return on Equity | 56.37% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
